<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03365960</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2017-078</org_study_id>
    <nct_id>NCT03365960</nct_id>
  </id_info>
  <brief_title>Bioavailability and Pharmacokinetic Parameters of Watermelon (Rind, Flesh and Seeds) Polyphenols</brief_title>
  <acronym>WM</acronym>
  <official_title>Bioavailability and Pharmacokinetic Parameters of Watermelon (Rind, Flesh and Seeds) Polyphenols in Human Plasma: A Pilot Study to Investigate Relationship to Endothelial Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Nutrition Research Center, Illinois Institute of Technology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Nutrition Research Center, Illinois Institute of Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are outlined below:&#xD;
&#xD;
        1. To investigate the relative bioavailability and absorption/kinetic profile of&#xD;
           polyphenols after consumption of watermelon rind, flesh and seeds, respectively in an&#xD;
           acute pilot study.&#xD;
&#xD;
        2. To study the effects of watermelon intake on endothelial function using the FMD&#xD;
           technique and to understand the relationship between plasma metabolites, including&#xD;
           L-citrulline and arginine, and FMD responses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed trial will be a randomized, 4 arm, placebo controlled, within-subject crossover,&#xD;
      study design. It is a pilot trial to establish methods and collect the preliminary data&#xD;
      (N=6). Subjects meeting eligibility criteria (see eligibility criteria) will participate in 4&#xD;
      study visits where they will receive one serving (equivalent to 100 kcal) of 1 of 4&#xD;
      treatments: watermelon rind, watermelon flesh, watermelon seeds or placebo.&#xD;
&#xD;
      Qualified subjects from the screening visit will be randomized into the study and provided&#xD;
      with a standard breakfast consisting of a high carbohydrate and moderate fat western-type&#xD;
      meal 3 hours after the treatment. Each subject will be asked to come for one screening visit,&#xD;
      a pre-study visit, and four dinner pick-ups on the day before each of the four test visits.&#xD;
      The study day visit will last for approximately 9 h with a follow up visit the next day (24&#xD;
      h) for blood collection to allow for the characterization of target watermelon polyphenols&#xD;
      and metabolites in plasma. Subjects will be instructed not to alter their usual diet or fluid&#xD;
      intake during the study periods. Seven days prior to each study day visit, subjects will be&#xD;
      advised not to consume fruits and vegetables rich in polyphenols and carotenoids or other&#xD;
      high phytochemical foods (watermelon and products, arugula, spinach, tea, berries, grapes,&#xD;
      carrots, tomatoes, sweet potatoes etc.).&#xD;
&#xD;
      Each study visit will involve with blood samples collection at time points 0 (fasting), 0.5,&#xD;
      1, 2, 3, 4, 5, 6, 7, 8 h and 24 hour (h). An assigned test treatment will be provided&#xD;
      immediately after the 0 h blood collection, a breakfast meal will be provided immediately&#xD;
      after the 2 h blood collection, and lunch after 6 h blood collection. FMD will be measured at&#xD;
      0 (fasting), 1, 3, 5, and 7h.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Actual">April 2, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative characterization of watermelon polyphenolic compounds in plasma over 24-hour in humans</measure>
    <time_frame>24-hour Postprandial period</time_frame>
    <description>This will be conducted by using ultra-high performance liquid chromatography iFunnel quadrupole time of flight mass spectrometer (UHPLC-QTOF-MS) and triple quadrupole mass spectrometer (UHPLC-QQQ-MS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes in endothelial function using ultrasound technique after consumption of each treatment</measure>
    <time_frame>24-hour Postprandial period</time_frame>
    <description>Flow Mediated Vasodilation imaging of the brachial artery to assess endothelial-dependent relaxation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the relationship between plasma metabolites and FMD responses after consumption of treatments</measure>
    <time_frame>24-hour Postprandial period</time_frame>
    <description>Correlation between plasma metabolites and FMD Change</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Active1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>watermelon rind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>watermelon flesh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>watermelon seeds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Watermelon Rind</intervention_name>
    <description>watermelon rind</description>
    <arm_group_label>Active1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Watermelon Flesh</intervention_name>
    <description>watermelon flesh</description>
    <arm_group_label>Active2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Watermelon Seeds</intervention_name>
    <description>watermelon seeds</description>
    <arm_group_label>Active3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control Comparator</description>
    <arm_group_label>Control Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Men or women, 20-45 years of age with body mass index (BMI) in range from 27.5-32&#xD;
             kg/m2&#xD;
&#xD;
               -  Nonsmokers (Past smokers can be allowed if they have abstinence for minimum of 2&#xD;
                  years)&#xD;
&#xD;
               -  No clinical evidence of cardiovascular, metabolic, respiratory, renal,&#xD;
                  gastrointestinal or hepatic disease&#xD;
&#xD;
               -  Not taking any medications that would interfere with outcomes of the study, i.e.&#xD;
                  lipid lowering medications, anti-inflammatory drugs, dietary supplements&#xD;
                  especially arginine and L-citrulline, etc.&#xD;
&#xD;
               -  Able to provide informed consent&#xD;
&#xD;
               -  Able to comply and perform the procedures requested by the protocol (including&#xD;
                  dietary restrictions, consumption of study treatments, records of food diary and&#xD;
                  questionnaire, and study visit schedule)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Men and women who smoke&#xD;
&#xD;
               -  Men and women with known or suspected intolerance, allergies or hypersensitivity&#xD;
                  to study foods or treatments&#xD;
&#xD;
               -  Men and women who consume &gt; 2 servings of watermelons per day&#xD;
&#xD;
               -  Men and women known to have/diagnosed with diabetes mellitus&#xD;
&#xD;
               -  Men and women who have fasting blood glucose concentrations &gt; 125 mg/dL&#xD;
&#xD;
               -  Men and women who have uncontrolled blood pressure &gt;140 mmHg (systolic)/90 mmHg&#xD;
                  (diastolic)&#xD;
&#xD;
               -  Men and women with documented vascular disease, e.g., heart failure, myocardial&#xD;
                  infarction, stroke, angina, related surgeries, etc. that, in the opinion of the&#xD;
                  investigator, could interfere with the interpretation of the study results&#xD;
&#xD;
               -  Men and women with cancer other than non-melanoma skin cancer in previous 5 years&#xD;
&#xD;
               -  Men and women diagnosed with chronic constipation, diarrhea or other chronic&#xD;
                  gastrointestinal complaint (e.g. irritable bowel syndrome)&#xD;
&#xD;
               -  Women who are known to be pregnant or who are intending to become pregnant over&#xD;
                  the course of the study&#xD;
&#xD;
               -  Women who are lactating&#xD;
&#xD;
               -  Taking medication or dietary supplements that may interfere with the outcomes of&#xD;
                  the study; e.g., antioxidant supplement, anti-inflammation, lipid lowering&#xD;
                  medication, blood pressure lowering medication, etc... Subjects may choose to go&#xD;
                  off dietary supplements (requires 30 days washout); e.g., fish oil, probiotics,&#xD;
                  etc...&#xD;
&#xD;
               -  Men and women who have donated blood within 3 months of the Screening Visit and&#xD;
                  blood donors/participants for whom participation in this study will result in&#xD;
                  having donated more than 1500 milliliters of blood in the previous 12 months.&#xD;
&#xD;
               -  Men and women who are vegans or vegetarian&#xD;
&#xD;
               -  History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge&#xD;
                  eating) diagnosed by a health professional&#xD;
&#xD;
               -  Substance (alcohol or drug) abuse within the last 2 years&#xD;
&#xD;
               -  Excessive coffee and tea consumers (&gt; 5 cups/d)&#xD;
&#xD;
               -  Men and women who do excessive exercise regularly or an athlete&#xD;
&#xD;
               -  Unstable weight: gained or lost weight +/- 5 kg (11 lbs) in previous 2 months&#xD;
&#xD;
               -  Women who are taking unstable dose of hormonal contraceptives and/or stable dose&#xD;
                  for less than 6 months&#xD;
&#xD;
               -  Unusual working hours i.e., working overnight (e.g. 3rd shift)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britt Burton-Freeman, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Illinois Institute of Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Nutrition Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Watermelon</keyword>
  <keyword>Watermelon phytochemicals bioavailability</keyword>
  <keyword>Flow Mediated Vasodilation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

